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Abstract BTLA (B- and T-lymphocyte attenuator) is a
prominent co-receptor that is structurally and functionally
related to CTLA-4 and PD-1. In T cells, BTLA inhibits
TCR-mediated activation. In B cells, roles and functions of
BTLA are still poorly understood and have never been
studied in the context of B cells activated by CpG via
TLR9. In this study, we evaluated the expression of BTLA
depending on activation and differentiation of human B cell
subsets in peripheral blood and lymph nodes. Stimulation
with CpG upregulated BTLA, but not its ligand: herpes
virus entry mediator (HVEM), on B cells in vitro and
sustained its expression in vivo in melanoma patients
after vaccination. Upon ligation with HVEM, BTLA
inhibited CpG-mediated B cell functions (proliferation,
cytokine production, and upregulation of co-stimulatory
molecules), which was reversed by blocking BTLA/
HVEM interactions. Interestingly, chemokine secretion
(IL-8 and MIP1β) was not affected by BTLA/HVEM
ligation, suggesting that BTLA-mediated inhibition is
selective for some but not all B cell functions. We
conclude that BTLA is an important immune checkpoint
for B cells, as similarly known for T cells.
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B cell activation requires several signals via the B cell
receptors (BCR) upon antigen binding and via various co-
activating and inhibitory receptors, mostly members of the
B7/CD28 co-receptor family. These molecules regulate nu-
merous checkpoints of immune cells functions, regulating
differentiation, maturation, adhesion, chemotaxis, and the
release of soluble factors. Several co-inhibitory receptors
have been identified, and the therapeutic blockade of these
molecules is in promising clinical development [1].
The recently described inhibitory receptor B- and T-
lymphocyte attenuator (BTLA, CD272) [2] is structurally
and functionally related to CTLA-4 and PD-1 and is
expressed by the majority of lymphocytes [2–4]. BTLA is
a type-I protein composed of one immunoglobulin super-
family domain, a trans-membrane domain and an intracel-
lular domain containing a proximal immuno-receptor
tyrosine-based inhibitory motif (ITIM) and a distal
immuno-receptor tyrosine-based switch motif (ITSM) [2].
Disruption of either the ITIM or ITSM abrogated the ability
of BTLA to recruit either Src homology region 2 domain-
containing phosphatase (SHP)-1 or SHP-2 [5], suggesting
that both tyrosine motifs are required to block lymphocyte
activation upon interaction with its ligand herpes virus entry
mediator (HVEM, CD270) [6]. HVEM is a member of the
tumor necrosis factor receptor family. BTLA/HVEM inter-
actions are involved in immune tolerance. Interestingly,
most BTLA studies were realized on T-lymphocytes. Stim-
ulation of BTLA was involved in the inhibition of T cell
proliferation and cytokine synthesis [6–9]. Mice deficient
for BTLA or HVEM both developed a deteriorated and
prolonged experimental autoimmune encephalomyelitis
[2]. There is only one study on the role of BTLA in B cells
showing that it regulates B cell receptor signaling by reduc-
ing the phosphorylation of SYK, B cell linker protein, and
the phospholipase C-γ2 [10]. Thus, the implication of
BTLA triggering for human B cells remains poorly
documented.
B cells express germline encoded Toll-like receptors
(TLRs), which have emerged as critical modulators of B
cell effector functions, notably in autoimmune diseases or
TH1-related inflammation [11]. TLRs are primarily associ-
ated with innate immunity as they are specialized for the
recognition of conserved motifs found on a broad range of
pathogens. Their triggering induces innate [12] then adap-
tive immune responses directed against the invading patho-
gens [13].
In humans, B cells are the only immune population
together with the plasmacytoid dendritic cells to express
TLR9 [14, 15]. TLR9 recognizes hypo-methylated CpG
motifs, characteristic of bacterial, viral, and protozoal
DNA, which can be mimicked by synthetic oligodeoxynu-
cleotides (ODNs), such as CpG motifs [16]. Stimulation of
TLR9 by CpG motifs initiates the intracellular MyD88-
mediated signaling pathway, resulting in the release of pro-
inflammatory cytokines [16] and plasmacytoid differentia-
tion, promoting B cell proliferation, class switch recombi-
nation, and antibody production. Initially, the direct
stimulation of TLR9 on B cells was implicated in the de-
velopment and pathogenesis of autoimmune diseases, such
as systemic lupus erythematosus [17, 18].
In this study, we investigated the role of BTLA in human
B cells. We show that BTLA expression is modulated during
B lymphocyte differentiation, with an enhanced expression
in IgM memory B cells. We analyzed BTLA expression by
B cells in vaccinated melanoma patients. When CpG were
used as adjuvant for vaccination, we observed a sustained
expression of BTLAwhereas, in absence of CpG, a progres-
sive downregulation of BTLA was found on circulating B
cells. Furthermore, we show that BTLA was upregulated
and recruited to the BCR in B cells activated in vitro.
Finally, we demonstrate that BTLA triggering by HVEM
attenuated human B cell proliferation, upregulation of co-
stimulatory molecules, and secretion of cytokines but not
chemokines. Altogether, our data demonstrate that BTLA
regulates human B cell responses and has implications for
future development of therapies modulating B cells.
Material and methods
Cells
Peripheral blood mononuclear cells were obtained from
volunteers and anonymous donors of Etablissement Fran-
çais du Sang. Peripheral leukocytes were isolated by Ficoll
density gradient centrifugation (Axis-Shield PoC AS, Nor-
way). The mononuclear cells were washed twice and con-
served in RPMI 1640 (GIBCO, Invitrogen) supplemented
with 10 % heat-inactivated fetal calf serum (Lonza, Bel-
gium). B cells were sorted using an EasySep® Human B
cell Enrichment Kit® (StemCell Technology) according to
manufacturer’s instructions. The purity and viability of
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sorted cells were systematically established and always great-
er than 95 %. The 293 T cells expressing human BTLA or not
(kindly provided by Dr. Claude Krummenacher, University of
Pennsylvania, Philadelphia, USA) were cultured in Dulbec-
co’s modified Eagle’s Medium (GIBCO, Invitrogen) supple-
mented with 10 % heat-inactivated fetal calf serum.
Patient and vaccination
HLA-A*0201-positive patients with stage III/IV metastatic
melanoma were included in the Ludwig Institute for Cancer
Research clinical trials LUD 96-010 and LUD 00-018,
approved by institutional review boards and regulatory
agencies [19, 20]. Patients received monthly low-dose vac-
cinations s.c. with 100 μg Melan-AMART-1 peptide. As de-
scribed in Lienard et al. and Speiser et al. [19, 20], CpG-
ODN (TCGTCGTTTTGTCGTTTTGTCGTT; 500 μg PF-
3512676/7909; provided by Pfizer/Coley Pharmaceutical
Group) was added where indicated. For all patients, vaccines
were formulated with incomplete Freund’s adjuvant (IFA)
(300–600 μl Montanide ISA-51), except for six patients in
the group “without CpG” who received no adjuvants (two
patients) or QS21 plus MPL (four patients) [19, 20].
Generation of anti-human BTLA monoclonal antibodies
and Fab fragmentation
Monoclonal antibodies (mAbs) recognizing BTLA (clones
7.1 and 8.2) were generated by immunization of Balb-c
mice with the respective recombinant human Fc-IgG1 fu-
sion proteins. After fusion, the hybridoma supernatants were
screened for staining of COS-7 transfected cells and for lack
of reactivity with untransfected cells. The blocking activity
of titrated BTLA8.2 mAb was assessed in a competition
assay based on the inhibition of recombinant human
HVEM-Fc (rhHVEM-Fc) binding to BTLA transiently
expressed on COS-7 cells, as described [7]. Generation of
Fab fragment was performed using papain enzymatic diges-
tion with ImmunoPure Fab Preparation Kit according to the
manufacturer’s protocol (Pierce).
Flow cytometry
The following antibodies were used for analysis of
circulating B cells from patients: FITC-conjugated-CD14,
R-Phycoerythrin (PE)-conjugated-anti-BTLA, and Amcyan-
conjugated-CD3 purchased from BD Biosciences, and Pa-
cific Blue-conjugated CD20 from Biolegend. Otherwise,
PE-conjugated-anti-IgD, FITC-conjugated-anti-CD27, 7-
amino-actin-D staining solution, and isotypic controls were
purchased from BD Biosciences; APC Alexa Fluor 780-
conjugated-anti-CD19 from eBioscience were used. Anti-
BTLA (clone 7.1) antibody was produced and conjugated in
our laboratory with Alexa Fluor® 647 Protein Labeling Kit
(Molecular Probes Invitrogen). For assessment of surface
molecules, cells were labeled with predetermined optimal
antibody concentrations according to the manufacturer’s
staining protocol. For evaluation of rhHVEM-Fc (R&D
Systems) binding specificity, 293 T cells expressing human
BTLA or not were stained with increasing doses of
rhHVEM-Fc, followed by staining with Alexa Fluor 647-
conjugated anti-human IgG (Jackson ImmunoResearch Lab-
oratories) and/or anti-BTLA-PE. Data acquisition was per-
formed on a Canto II or LSR II cytometer and analyzed
using FlowJo Software (Treestar).
Gene expression from DNA microarrays
Public Affymetrix U133 data sets from purified naïve, IgM
memory, switched memory, and transitional B cells were
retrieved from the public Gene Expression Omnibus (GEO)
data sets GSE22886 [21] and GSE17186 (http://
www.ncbi.nlm.nih.gov/gds) [22]. We used robust multichip
average (RMA) analysis with the non-parametric quantile
algorithm as normalization parameter. RMA was applied to
the raw data and then quantile normalization and Loess’cor-
rection were done in R software using Bioconductor and
associated packages. The probe sets corresponding to BTLA
(236226_at) and to HVEM (209354_at) were retrieved from
the normalized data sets and the subsequent log value was
linearized for graphical representation.
Proliferation assays and ELISA
Purified B cells were resuspended in phosphate buffered
saline (PBS) at 1×107cells/ml and incubated for 10 min at
37 °C with 2,5 μM carboxyfluoresceine diacetate succini-
midyl ester (CFSE, Molecular Probes Invitrogen) for assess-
ment of proliferation. After washing, cells were activated by
2 μg/ml of ODN 2006-CpG (Invitrogen) or CpG Pfizer/
Coley Pharmaceutical Group and cultured for 5 days with
10 μg/ml of soluble or plate-bound rhHVEM-Fc chimera
(R&D Systems) or with Control-Fc (Ctrl-Fc) fusion protein
(Mutated Thy-1-Fc, Alexis Biochemicals). After 2 days,
50 μl of culture supernatant were tested for the presence
of cytokines or chemokines by Cytokines Beads Array (BD
Biosciences) or ELISA (R&D Systems), respectively. When
indicated, 10 μg/ml of blocking anti-BTLA Fab fragment
(clone 8.2) were added to the culture [7, 23].
Immunofluorescence
Coverslips were coated during 30 min with poly-L-lysine
(Sigma-Aldrich). Sorted B cells grown on coverslips were
fixed in methanol at −20 °C for 6 min and rinsed in PBS.
After blocking in PBS 5 % bovine serum albumin (BSA),
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cells were incubated with primary antibodies diluted in
PBS–BSA for 30 min. After washing in PBS 0.1 %
Tween20, primary antibodies were detected using anti-Ig
secondary antibodies conjugated to cyanine 5 from Jackson
Laboratories or Alexa Fluor 488 from Invitrogen. Nuclei
were stained with 250 ng/ml of 4',6-diamidino-2-phenyl-
indole (DAPI; Roche Diagnostics). Cells were mounted in
Prolong Gold anti-fade reagent (Invitrogen) and examined
on an LSM-510 Carl Zeiss confocal microscope with a ×63
NA1.4 plan Apochromat objective. Optical sections were
projected with LSM Software (Zeiss). For each experiment,
a minimum of 100 B cells was analyzed.
Statistical analysis
Results are expressed as mean±SEM. Statistical analyses
were evaluated using two-tailed non-parametric unpaired
Mann–Whitney t test when comparing two groups of differ-
ent donors or with the non-parametric paired Wilcoxon’s t
test when comparing same donors in different conditions.
All tests were performed with the GraphPad Prism® statis-
tical analysis program. The Pearson correlation test was
used to demonstrate significant inverse correlation between
BTLA expression and numbers of vaccinations (Fig. 1).
Only p values<0.05 were considered as significant.
Results
Progressive downregulation of BTLA by B cells in vivo
is reversed by vaccination when using CpG as adjuvant
CpG can enhance both innate and adaptive immunity and
consequently, has a potential utility for immunotherapeutic
and vaccine adjuvant applications. CpGs mediate their
effects through the triggering of TLR9, which is only
expressed by plasmacytoid dendritic cells and B cells in
humans [24]. We recently reported that vaccinations of
melanoma patients with peptides and CpGs lead to BTLA
downregulation on tumor antigen-specific T cells [7]. We
therefore addressed whether CpG vaccination altered BTLA
expression on B cells from peripheral blood mononuclear
cells (PBMC). Patients received serial monthly subcutane-
ous vaccinations with Melan-A/MART-1 peptide in conven-
tional vaccine formulations, e.g., emulsified in IFA [19]. A
second cohort of patients was treated similarly, except that
CpG oligodeoxynucleotides were added to the vaccine for-
mulation, resulting in a considerably enhanced CD8+ T cell
response, as previously reported [20]. Representative anal-
yses of BTLA expression by B cells from vaccinated
patients are shown in Fig. 1a. We observed a progressive
BTLA downregulation in patients vaccinated without CpG
Fig. 1 Sustained BTLA expression upon repeated vaccination with
CpG. aMelanoma patients received monthly peptide vaccinations with
or without CpG, emulsified in IFA (Montanide ISA-51). Representa-
tive histograms of BTLA staining gated on CD20+ B cells (after
exclusion of doublets, dead cells, CD14+ monocytes and CD3+ T
cells) of PBMCs from five patients, before vaccination (patient
LAU465), and after repeated monthly vaccinations, i.e., four
(LAU321), nine (LAU42, LAU701), 16 (LAU465), and 19
(LAU1106) vaccinations. Mean fluorescence intensity (MFI) of BTLA
(and percentage of BTLAhigh in parentheses) is indicated. b Correla-
tions between numbers of vaccinations without CpG (n035) or with
CpG (n026) and the MFI of BTLA expressed by circulating B cells.
Pearson correlation R2 and P values are indicated
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(Fig. 1a), which significantly correlated with the number of
monthly booster vaccinations (Fig. 1b). In contrast, patients
vaccinated with CpG showed a sustained expression of
BTLA by B cells (Fig. 1a, b), suggesting that CpG activa-
tion of B cells results in maintenance of BTLA expression.
Similar results were obtained when data were evaluated in
terms of percentage of BTLAhigh B cells (data not shown).
BTLA is overexpressed on IgM memory B cells
In order to investigate the expression of BTLA on B cells in
relation to their differentiation stage, we performed ex vivo
multicolor flow cytometry analysis on PBMCs from healthy
donors. Using a combination of markers including CD19,
immunoglobulin (Ig) D, CD27, and BTLA, we were able to
look at BTLA expression on naïve (CD19+IgD+CD27−),
classical isotype switched memory (CD19+IgD−CD27+)
and IgM memory B cells (CD19+IgD+CD27+) [25], as
depicted in Fig. 2a. We also examined BTLA mRNA ex-
pression in B cell subsets from purified naïve IgM memory,
switched memory, and transitional B cells from the public
GEO datasets GSE22886 [21] and GSE17186 [22] (Supple-
mental Fig. 1A). Interestingly, although BTLA was
expressed by all B cell subsets, its expression was signifi-
cantly lower in naïve and memory B cells subsets compared
with IgM memory B cells (Fig. 2b upper panel and Supple-
mental Fig. 1A) and was even higher on transitional (CD27
−IgD+CD24high and CD38high) circulating B cells (Supple-
mental Fig. 1A and data not shown) [26], demonstrating that
BTLA expression changes during B cell differentiation.
Moreover, we also analyzed HVEM expression on B cell
differentiation subsets. In contrast to BTLA, we did not find
any change in HVEM expression depending on differentia-
tion stages (Fig. 2b, lower panel). This was confirmed by
HVEM mRNA expression analysis from public GEO data-
sets (Supplemental Fig. 1B).
CpG induces upregulation of BTLA on BTLAlow B cells
Next, we analyzed whether BTLA expression alters while B
cells are activated. Thus, purified B cells from healthy
individuals were cultured in presence or absence of CpG.
Kinetic analysis revealed that, in medium alone (Fig. 3a), B
cells progressively reduced BTLA expression. Almost half
of B cells had a low expression of BTLA at day 5 (Supple-
mental Fig. 2). In contrast, B cells stimulated with CpG
maintained the expression of BTLA (Fig. 3a and Supple-
mental Fig. 2). Interestingly, HVEM expression is not mod-
ulated upon CpG stimulation (data not shown). These
results suggest that CpG-mediated activation of B cells
sustain and/or increased BTLA expression. It has recently
been shown that germinal center (GC) B cells from lymph
nodes do not express BTLA [27], in contrast to B cells from
PBMCs (Fig. 2) [9]. Therefore, in order to better understand
Fig. 2 Differential expression
of BTLA during B cell
differentiation. a Gating strategy
for the identification of B cell
subsets. CD19+ B cells from
healthy volunteer PBMCs were
analyzed for IgD and CD27
expression to characterize the
following subsets: naïve IgD+
CD27−, IgM memory IgD+
CD27+, andmemory B cells IgD
− CD27+ (upper panel). BTLA
expression was analyzed in each
subset as shown for a
representative example (lower
panel): isotype control (grey),
naïve (dotted line), IgM memory
(dashed line), and memory
(black line). b Statistical
assessment of BTLA (upper
panel) and HVEM (lower panel)
expression on B cell subsets
(n017). Statistical analysis
between medium and CpG point
at each time using two-tailed
non-parametric unpaired Mann–
Whitney t test. P<0.01 and P<
0.001 are indicated by ** and
***, respectively
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the effect of CpG on BTLA expression, we sorted BTLAneg/
low and BTLAhigh B cells from normal lymph nodes,
stimulated them with or without CpG, and assessed the
expression of BTLA after 5 days of culture (Fig. 3b).
When comparing BTLA expression before and after cul-
ture in medium alone, it appears that the decrease of
BTLA observed in Fig. 3a occurs only in B cells express-
ing high levels of BTLA. Interestingly, upon CpG stimu-
lation, we found a significant upregulation of BTLA
expression on both sorted B cells populations, although
this augmentation did not reach the expression level be-
fore culture (Fig. 3c). These data demonstrate that activa-
tion with CpGs resulted in enhanced BTLA expression on
B cells.
BTLA is recruited to BCR upon CpG activation
Next, we investigated the localization of BTLA. Purified B
cells were activated by CpG and, subsequently CD19, used
as a surrogate marker of BCR that propagates BCR micro-
signalosomes spreading [28], and BTLA distribution were
assessed by confocal microcopy. Whereas no clustering was
observed without activation (Fig. 4a, time 0 min), we found
that, 15 min after incubation with CpG, BTLA accumulated
and co-localized with the BCR in 55 % of observed B cells
(Fig. 4a, b). These results suggest that BTLA is translocated
to the BCR’s cluster upon CpG activation. Interestingly, the
same accumulation of BTLA was obtained when B cells
were directly stimulated through the BCR with an anti-IgM
antibody (Supplemental Fig. 3).
BTLA/HVEM-mediated selective inhibition of proliferation
and cytokine production
We evaluated whether BTLA could inhibit B cell functions.
First, we analyzed the proliferation of purified B cells from
healthy donors by CFSE dilution. After 5 days of CpG
stimulation, expansion of B cells was significantly attenuat-
ed in the presence of plate-bound or soluble rhHVEM-Fc
protein (Fig. 5a, b), which is able to specifically bind to
BTLA (Supplemental Fig. 4A). The addition of Fab frag-
ment from an anti-BTLA blocking mAb [7, 23] restored B
cell proliferation (Fig. 5b), showing that BTLA indeed
inhibited CpG-mediated B cell proliferation. In addition, B
cell survival was not affected by either rhHVEM-Fc or Fab
fragment (Supplemental Fig. 5). In this experiment, we also
assessed B cell activation, as B cell activation by TLR
agonists induces expression of CD86 and CD80 [29]. As
shown in Fig. 5c, B cells showed significantly lower CD80
and CD86 expression in the presence of rhHVEM-Fc,
whereas HLA-DR expression did not change (data not
shown). Similar results were obtained when analyzing MFI
of CD80 and CD86 (data not shown). Again, this effect was
reversed in the presence of blocking BTLA Fab fragment
(Fig. 5c). Interestingly, we also observed that the presence
Fig. 3 Maintenance of BTLA expression on B cells upon stimulation
with CpG in vitro. a Kinetic analysis of BTLA surface expression
during CpG stimulation. Purified B cells from healthy individuals
PBMCs were cultured from 1 to 5 days with or without CpG (2 μg/
ml). b Representative experiment depicting BTLA expression by
sorted BTLA high and BTLA neg/low CD19+ B cells from normal
lymph nodes (NLN) after 5 days of culture with or without CpG (2 μg/
ml). MFI of BTLA (and percentages of BTLAhigh in parentheses) is
indicated. c Statistical analysis of this experiment, i.e., of B cells sorted
as “BTLA high” and as “BTLA neg/low” and stimulated with (black
bars) or without CpG (white bars) for 5 days (n05). Gray bars
represent MFI of BTLA in each sorted populations before culture.
Comparisons were evaluated using two-tailed non-parametric paired
Wilcoxon’s t test. P<0.05, P<0.01, and P<0.001 are indicated by *,
**, and ***, respectively
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of rhHVEM-Fc molecules led to the downregulation of
BTLA on B cells, independently of the presence of CpG
(Fig. 5d). Besides, the possibility of binding competition
between rhHVEM-Fc and anti-BTLA mAb was ruled out
because labeling of rhHVEM-Fc on 293 T cells expressing
BTLA (Supplemental Fig. 4A) did not preclude anti-BTLA
mAb staining (Supplemental Fig. 4B). All together, these
results suggest a regulation of BTLA by its own ligand, as
we already showed for CD8+ T cells [7].
In parallel, we measured the secretion of inflammatory
cytokines by B cells after 2 days of stimulation with CpG.
We found a significant reduction of IL-6, IL-10, and TNFα
production when B cells were stimulated in presence of
rhHVEM-Fc molecules (Fig. 6a). As observed for prolifer-
ation and activation marker expression, the addition of
blocking anti-BTLA Fab fragment rescued B cell IL-6 se-
cretion (data not shown). Interestingly, IL-8 and MIP1-β
were not affected by BTLA-mediated inhibition upon CpG
stimulation (Fig. 6b). Together, these data revealed an in-
hibitory role of BTLA in CpG-induced B cell proliferation
and a specific inhibition of cytokine but not chemokine
secretion.
Discussion
The co-receptor BTLA is widely expressed on immune cells
but has mainly been investigated on T cells where it attenu-
ates T cell activation and proliferation [3, 7, 8, 23]. Only
little is known on the role and the function of BTLA in B
cells. In this study, we described the regulation of BTLA
expression in CpG-activated B cells, both ex vivo and in
vivo. Our study highlights a mechanism by which the
BTLA/HVEM pathway modulates B cell functions.
BTLA is expressed on T cells [2] and B cells (Fig. 2),
with a higher expression on the latter [3]. It has been
suggested that BTLA does not have a pivotal role in human
B cell development in the bone marrow, since only mature
bone marrow B cells, compared with precursor B cells,
expressed BTLA [10]. In a complementary manner and in
Fig. 4 Co-localization of
BTLA and CD19 on CpG-
activated B cells. a Representa-
tive experiment (out of five) of
BTLA and CD19 distribution
on resting and CpG-activated
purified B cells. Cells were
fixed and permeabilized and
then stained with anti-BTLA7.1
(red) and anti-CD19 (green)
mAbs. Nuclei were finally
stained with DAPI (blue).
Images were analyzed by con-
focal microscopy. Yellow
results from the overlay of red
and green signals. b Co-
localization of CD19 and
BTLA on the B-lymphocyte
cell surface from images
depicted in a at 15 min. The
white arrow corresponds to the
X-axis of the histogram
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contrast to HVEM, our data showing a differential expres-
sion of BTLA among circulating B cell subsets, suggest a
role of BTLA during B cell differentiation (Fig. 2 and
Supplemental Fig. 1). We found that circulating transitional
and IgM memory B cells express higher levels of BTLA
compared with naïve and memory B cells, including
switched memory B cells. Transitional B cells correspond
to the most immature B cell type in peripheral blood and
represent a critical early step, in which BTLA may presum-
ably be implicated, in the differentiation and selection of
mature B cells [30]. IgM memory B cells are generated in T
cell-independent reactions and do not seem to require GC
formation [31, 32]. These cells are important to elicit im-
munoglobulin production in the absence of T cell stimula-
tion. Recently, these cells were suggested to recirculate from
the spleen marginal zone [33]. Our results suggest that
BTLA might be an important regulator of T cell-
independent-Ig production. Besides, GC B cells do not
express BTLA, in contrast to naïve B cells from the mantle
zone of lymph nodes [27]. These results and ours underlie
the putative role of BTLA in the peripheral differentiation of
B cells.
BTLA is known to inhibit T cells in mice and humans
(reviewed in [34]). However, little is known on the impact
of BTLA on B cell functions. Few studies reported that
BTLA−/− mice show increased specific antibody responses
and autoimmune hepatitis associated with auto-antibodies
[2, 35], highlighting a potential role of BTLA in regulating
B cells autoimmunity. Our data demonstrate that BTLA
inhibited CpG-mediated B cell function in humans, suggest-
ing that BTLA may compromise B cell-dependent protec-
tion from infection. Indeed, we showed for the first time that
CpG directly upregulated BTLA on B cells in vitro (Fig. 3)
and at least sustains its expression in vivo (Fig. 1), in
contrast to T cells [7]. Activation of B cells leads to the
co-localization and accumulation of BTLA with the BCR
(Fig. 4), suggesting a link between the signaling pathway of
CpG and BCR [36, 37]. Furthermore, ligation of BTLAwith
Fig. 5 BTLA-mediated inhibition of B cell proliferation. a CFSE-
labeled B cells were activated with CpG (2 μg/ml) and cultured for
5 days with Ctrl-Fc or rhHVEM-Fc. In addition, blocking anti-BTLA
Fab fragment or isotype control was added into the culture. Histograms
depict one representative experiment. b Proliferation of B cells after
CpG stimulation with or without rhHVEM-Fc (n014). The prolifera-
tion ratio was calculated as the percentage of CFSEhigh divided by the
percentage of CFSElow B cells; low ratio implies high level of
proliferating B cells. c Analysis of CD80 and CD86 expression by
CpG-stimulated B cells upon BTLA/HVEM triggering (n07). d BTLA
is downregulated on B cells upon HVEM ligation. Expression of
BTLA by purified B cells after stimulation with CpG (2 μg/ml) with
or without rhHVEM-Fc (n08). Statistical analysis was evaluated using
two-tailed non-parametric paired Wilcoxon’s t test. P<0.05, P<0.01
and P<0.001 are indicated by *, ** and ***, respectively
202 J Mol Med (2013) 91:195–205
HVEM decreases B cell proliferation (Fig. 5a), as described
previously [10]. In addition, we show that cytokine secre-
tion (IL-6, IL-10, and TNFα) and upregulation of co-
stimulatory markers (CD80 and CD86) were also dampened
by BTLA triggering (Figs. 5 and 6). Interestingly, the pro-
duction of chemokines (IL-8 and MIP1β) was not affected
(Fig. 6b), underlying a dichotomy in the inhibitory capaci-
ties of BTLA, as previously shown for CD8+ T cells [7].
This suggests that the inhibition of B cells by BTLA may
alter their effector functions but not their capacity to attract
other immune cells. All together, these results emphasize the
importance of BTLA as B cell activation checkpoint. A recent
mouse study showed that B cells might contribute to innate
immunity against bacterial infection, primarily through TLR4
triggering and GM-CSF secretion. It will be interesting to
determine whether BTLA may be involved in the regulation
of such B cell populations activated via TLR4 [38].
Recently, CD160 was identified as another co-inhibitory
receptor that can also bind HVEM, resulting in the inhibi-
tion of CD4+ T cells [39]. However, it is unlikely that this
interaction plays a role in B cell physiology, as CD160 is not
expressed on B cells [40, 41]. HVEM can bind further
proteins, namely LIGHT, lymphotoxin α, and glycoprotein
D, but the only ligand present on mature, naive B cells is
BTLA [39, 40, 42], which thus appears as the major inter-
acting partner during the initial steps of B cell activation
process by CpG. Since B cell tumors express TLR9, CpG
can directly affect them, but also indirectly via CpG-
activated dendritic cells. Thus, it influences B cell malig-
nancy viability (i.e., proliferation, apoptosis) and upregu-
lates MHC, co-stimulatory molecules, and other markers
such as CD20 and possibly BTLA that serve as targets in
immunotherapy approaches [43]. BTLA is one of the few
inhibitory receptors expressed by all B cells and also by B
cell lymphomas, especially chronic lymphocytic leukemia/
small lymphocytic lymphoma (B-CLL/SLL) [27]. Since we
showed that BTLA may dampen B cell functions, the use of
agonistic anti-human BTLA mAb in B-CLL/SLL patients
may eventually reduce tumor proliferation. Therefore, trig-
gering the BTLA inhibitory pathway in B cell malignancies,
likely in combination with other agents, may be considered
as a new strategy of targeted therapy.
In addition to their role in innate immunity [12], TLRs
are critically involved in the initiation and enhancement of
adaptive immune response. Enhanced immune response has
been reported in mouse tumor models using TLR9 agonists
not only as monotherapy but also in combination with other
therapies [44]. However, it remains questionable whether
these findings are applicable to immunomodulatory strate-
gies for patients. According to some recent clinical studies,
CpG have anti-tumor activity as single agents [43, 44] and
enhance the development of anti-tumor-specific T cells
responses when used as vaccine adjuvant [20, 44]. More-
over, CpG adjuvanted vaccination of melanoma patients
lead to BTLA downregulation on tumor-specific human
CD8+ T cells, concomitant with restoration of their func-
tionality [7]. Here, we show that this type of vaccination
additionally sustains BTLA expression on circulating B
cells in vivo (Fig. 1), which would most likely decrease
their functionality in case of ligation with HVEM. However,
HVEM has been recently reported to have co-stimulatory
function upon ligation with BTLA [45]. Therefore, we may
Fig. 6 Selective inhibition of cytokine secretion by BTLA. a Analysis
of cytokine production after 2 days of stimulation of B cells with CpG
in presence of rhHVEM-Fc or Ctrl-Fc (n06). b Analysis of chemokine
secretion by CpG-stimulated B cells cultured with or without Ctrl-Fc or
rhHVEM-Fc. Statistical analysis was evaluated using two-tailed non-
parametric paired Wilcoxon’s t test. P<0.05 and P<0.01 are indicated
by * and **, respectively
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hypothesize that, upon vaccination, a BTLA/HVEM bidi-
rectional pathway may occur. BTLA expressed by CpG-
activated B cells that present vaccine peptides may trigger
HVEM expressed by vaccine-specific T cells, possibly lead-
ing to enhanced T cell activation.
In summary, BTLA/HVEM ligation results in the inhibi-
tion of activated B cell functions. Our results underlie the
potential role of BTLA/HVEM interactions in vaccination
when using an adjuvant that stimulates B cells and provides
a baseline for further investigation of targeting BTLA in B
cell-related diseases.
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